320406-73-3Relevant academic research and scientific papers
OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF
-
, (2013/09/26)
Compounds of Formula (I) and Formula (II) are useful inhibitors of tankyrase. Compounds of Formula (I) and Formula (II) have the following structure: where the definitions of the variables are provided herein.
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors
Bregman, Howard,Chakka, Nagasree,Guzman-Perez, Angel,Gunaydin, Hakan,Gu, Yan,Huang, Xin,Berry, Virginia,Liu, Jingzhou,Teffera, Yohannes,Huang, Liyue,Egge, Bryan,Mullady, Erin L.,Schneider, Steve,Andrews, Paul S.,Mishra, Ankita,Newcomb, John,Serafino, Randy,Strathdee, Craig A.,Turci, Susan M.,Wilson, Cindy,Dimauro, Erin F.
, p. 4320 - 4342 (2013/07/19)
Tankyrase (TNKS) is a poly-ADP-ribosylating protein (PARP) whose activity suppresses cellular axin protein levels and elevates β-catenin concentrations, resulting in increased oncogene expression. The inhibition of tankyrase (TNKS1 and 2) may reduce the levels of β-catenin-mediated transcription and inhibit tumorigenesis. Compound 1 is a previously described moderately potent tankyrase inhibitor that suffers from poor pharmacokinetic properties. Herein, we describe the utilization of structure-based design and molecular modeling toward novel, potent, and selective tankyrase inhibitors with improved pharmacokinetic properties (39, 40).
Imidazopyridinone derivatives and their use as phosphodiesterase inhibitors
-
, (2008/06/13)
A compound (Ia): wherein the variables are defined in the specification, its prodrug or a pharmaceutically acceptable salt thereof useful in the treatment of angina, hypertension etc.
